secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091201
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics Q2 net loss $91.1M; cash $1.0B; BEAM-101 enrollment tops 20, six dosed
--------------------------------------------------------------------------------

- Net loss widened to $91.1M ($1.11/shr) from $82.8M ($1.08/shr) in Q2 2023.
- Cash, cash equivalents and marketable securities $1.0B at June 30 vs $1.2B at Dec 31, 2023.
- BEAM-101 Phase 1/2 BEACON trial: >20 patients enrolled, 6 dosed; initial data submitted for ASH.
- FDA cleared IND for BEAM-301 (GSDIa); patient dosing expected in early 2025.
- First patient dosed in BEAM-302 Phase 1/2 trial (AATD); initial clinical data expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024091201/0000950170-24-091201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024091201/beam-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer